Placebo News and Research

RSS

Viewpoints: Disability insurance 'time bomb;' Leavitt on the lessons of Medicare Part D's rollout; Boys and eating disorders

Social Security for retirement and Medicare are the best known of the major entitlement programs with looming financial disasters. While some argue about when they will run out of money, their projected 75-year unfunded liabilities grow larger every year and now total $40 trillion, much worse thereafter. But the ticking time bomb of entitlement reform is Social Security's Disability Insurance Fund (Michael J. Boskin, 7/14).

16 Jul 2013

Alize Pharma initiates AZP-531 Phase I clinical trial for treatment of type 2 diabetes

Alize Pharma, a company specialized in the development of drugs for the treatment of metabolic diseases and rare diseases, announces today the launch of the first Phase I clinical trial for AZP-531, its unacylated ghrelin analog, in type 2 diabetes.

16 Jul 2013

Furiex Pharmaceuticals enrolls patient for Phase III clinical trial of eluxadoline for treatment of diarrhea

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced completion of patient enrollment in the company's two ongoing Phase III clinical trials studying eluxadoline for the treatment of diarrhea-predominant irritable bowel syndrome, or IBS-d. Both studies met their target enrollments and Furiex expects to release top line results in the first quarter of 2014.

16 Jul 2013

Coffee and appetite: an interview with Matt Schubert and Associate Professor Ben Desbrow, Griffith University

We wanted to do something a bit different than the “typical” work on caffeine and exercise, and I have considerable interest in appetite regulation, so we built up from there.

15 Jul 2013

RXi Pharmaceuticals reports positive results from second Phase 1 study with RXI‑109

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced positive results from their second placebo-controlled Phase 1 study with RXI‑109, an sd-rxRNA compound that targets Connective Tissue Growth Factor, and is being developed for the treatment of abnormal dermal scars such as hypertrophic scars and keloids in conjunction with scar revision surgery.

12 Jul 2013

Clinical trial begins on ultrasound in combination with tPA to treat acute ischemic stroke

An international, Phase III clinical trial studying ultrasound in combination with a clot-busting medication to treat acute ischemic stroke has begun at The University of Texas Health Science Center at Houston (UTHealth).

12 Jul 2013

Aflibercept drug shows minor added benefit for overall survival in colorectal cancer patients

The drug aflibercept (trade name: Zaltrap) has been approved in Germany since February 2013 in combination with a certain chemotherapy for adults with metastatic colorectal cancer in whom chemotherapy with oxaliplatin could not stop the disease from progressing.

12 Jul 2013

Auspex enrolls first patient in SD-809 Phase 3 trial for treatment of chorea associated with HD

Auspex Pharmaceuticals announced today that the first patient has been enrolled in a multi-center Phase 3 pivotal trial of its lead investigational drug, SD-809 for the treatment of involuntary movements (chorea) associated with Huntington's Disease.

12 Jul 2013

Alnylam releases positive top-line data from ALN-TTRsc Phase I trial for TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive top-line results from its ongoing Phase I trial of ALN-TTRsc, a subcutaneously administered RNAi therapeutic targeting the transthyretin gene for the treatment of TTR-mediated amyloidosis.

12 Jul 2013

New report says most psychological intervention studies do not account for placebo effect

Many brain-training companies tout the scientific backing of their products - the laboratory studies that reveal how their programs improve your brainpower. But according to a new report, most intervention studies like these have a critical flaw: They do not adequately account for the placebo effect.

12 Jul 2013

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that its phase III study (MM-020/IFM 07-01) of REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma met its primary endpoint of progression-free survival.

11 Jul 2013

Bristol-Myers Squibb, Pfizer announce FDA acceptance of Eliquis sNDA for review

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration has accepted for review a Supplemental New Drug Application for Eliquis (apixaban), for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, in adult patients who have undergone hip or knee replacement surgery.

11 Jul 2013

Ohr Pharmaceutical enrolls first 60 patients in OHR-002 Phase II clinical trial for wet-AMD treatment

Ohr Pharmaceutical, Inc., a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced that it has enrolled the first 60 patients in the Company's ongoing OHR-002 Phase II clinical trial evaluating Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration.

10 Jul 2013

Physicians discuss use of new guidelines on aromatase inhibitor to prevent breast cancer

The American Society of Clinical Oncology (ASCO) is now recommending that physicians discuss use of the aromatase inhibitor exemestane (Aromasin) to prevent breast cancer in at-risk postmenopausal women.

10 Jul 2013

TGA of Australia approves Vertex Pharmaceuticals' KALYDECO for cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced that the Therapeutic Goods Administration of Australia has approved KALYDECO (ivacaftor) for people with cystic fibrosis ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator gene.

10 Jul 2013

Study shows rates of brain loss caused by aging and AD are higher for women

The rates of regional brain loss and cognitive decline caused by aging and the early stages of Alzheimer's disease (AD) are higher for women and for people with a key genetic risk factor for AD, say researchers at the University of California, San Diego School of Medicine in a study published online July 4 in the American Journal of Neuroradiology.

10 Jul 2013

Soy protein supplement does not reduce recurrence of prostate cancer post radical prostatectomy

Among men who had undergone radical prostatectomy, daily consumption of a beverage powder supplement containing soy protein isolate for 2 years did not reduce or delay development of biochemical recurrence of prostate cancer compared to men who received placebo, according to a study in the July 10 issue of JAMA.

10 Jul 2013

Individualised care can make huge difference in older patients with type 2 diabetes

More than a quarter of over 70s with type 2 diabetes could benefit simply from improving communication and education in the clinic, new research has revealed. A study led by the University of Exeter Medical School and published in The Lancet found that 27 percent achieved better glycaemic control through individualised care alone.

9 Jul 2013

Soligenix announces personalized medicine collaboration with SciClone

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced a personalized medicine collaboration with SciClone Pharmaceuticals in the Company's oral mucositis clinical program with SGX942.

8 Jul 2013

Study describes how human mammary gland becomes highly sensitive to insulin during lactation

Why do so many mothers have difficulty making enough milk to breastfeed? A new study by scientists at Cincinnati Children's Hospital Medical Center and the University of California Davis adds to their previous research implicating insulin's role in lactation success.

6 Jul 2013

Placebo News and Research

Viewpoints: Disability insurance 'time bomb;' Leavitt on the lessons of Medicare Part D's rollout; Boys and eating disorders

Alize Pharma initiates AZP-531 Phase I clinical trial for treatment of type 2 diabetes

Furiex Pharmaceuticals enrolls patient for Phase III clinical trial of eluxadoline for treatment of diarrhea

Coffee and appetite: an interview with Matt Schubert and Associate Professor Ben Desbrow, Griffith University

RXi Pharmaceuticals reports positive results from second Phase 1 study with RXI‑109

Clinical trial begins on ultrasound in combination with tPA to treat acute ischemic stroke

Aflibercept drug shows minor added benefit for overall survival in colorectal cancer patients

Auspex enrolls first patient in SD-809 Phase 3 trial for treatment of chorea associated with HD

Alnylam releases positive top-line data from ALN-TTRsc Phase I trial for TTR-mediated amyloidosis

New report says most psychological intervention studies do not account for placebo effect

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Bristol-Myers Squibb, Pfizer announce FDA acceptance of Eliquis sNDA for review

Ohr Pharmaceutical enrolls first 60 patients in OHR-002 Phase II clinical trial for wet-AMD treatment

Physicians discuss use of new guidelines on aromatase inhibitor to prevent breast cancer

TGA of Australia approves Vertex Pharmaceuticals' KALYDECO for cystic fibrosis

Study shows rates of brain loss caused by aging and AD are higher for women

Soy protein supplement does not reduce recurrence of prostate cancer post radical prostatectomy

Individualised care can make huge difference in older patients with type 2 diabetes

Soligenix announces personalized medicine collaboration with SciClone

Study describes how human mammary gland becomes highly sensitive to insulin during lactation

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News